Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with VTP-300 and low dose nivolumab
In a Phase 1a/1b clinical trial, AB-101, an oral PD-L1 inhibitor, has shown to be generally safe and well-tolerated with evidence of high receptor occupancy and no liver dysfunction in cHBV patients
WARMINSTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the presentation of five posters, including one late-breaker, highlighting imdusiran, its RNAi therapeutic and AB-101, its oral PD-L1 inhibitor, at the European Association for the Study of the Liver (EASL) Congress 2025.
In a late-breaker poster presentation, the following select key end-of-study data were reported from the Phase 2a clinical trial (IM-PROVE II, AB-729-202) evaluating stable nucleos(t)ide analogue (NA) therapy throughout the treatment period with imdusiran (60mg every 8 weeks) for 24 weeks and either Barinthus Biotherapeutic's T-cell stimulating immunotherapeutic VTP-300 without nivolumab (Group A, n=20) or with low dose nivolumab (Group C, n=22; 13 received nivolumab) or placebo (Group B, n=20):
- Three patients in Group C with the addition of nivolumab had HBsAg loss (HBsAg